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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the eDicacy and costs of psychological interventions (alone, or with CR or pharmacotherapy, or both) in adults who have a
diagnosis of CHD, HF or AF compared to no intervention, or treatment as usual, on psychological and clinical outcomes.
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B A C K G R O U N D
Description of the condition
For the purpose of this Cochrane systematic review, heart disease
(HD) will encompass three of the most common cardiovascular
conditions: coronary heart disease (CHD), heart failure (HF)
and atrial fibrillation (AF). CHD is the number one cause of
death, accounting for 9.43 million deaths worldwide in 2016,
approximately 4.95 million men and 4.48 million women (WHO
2018). HF and AF are cardiovascular disease (CVD) epidemics
with similar underlying risk factors and pathophysiology and
increasingly reported incidence (Benjamin 2017; Staerk 2017).
People with HD experience substantial burden that includes
fatigue, shortness of breath, poor health-related quality of life
(HRQoL), increased risk of mortality and hospital admissions, and
high healthcare costs (Garster 2009; Gheorghe 2018; Giedrimiene
2017; Long 2019; Schmidt 2016).
Over the past two decades significant reductions in mortality
have been achieved in people with HD through pharmacological
and device therapy (Anderson 2014; Mensah 2017). Subsequently
the focus has shiLed towards psychological outcomes (Richards
2018; Wan 2014). Depression and anxiety are highly prevalent
in people diagnosed with CHD, HF and AF, and result in worse
outcomes, such as poorer HRQoL, and increased morbidity and
mortality (Dhar 2016; Freedland 2015; Gale 2014). With the aim
of improving patient outcomes, psychological approaches tackling
stress management are included in cardiovascular prevention
guidelines internationally (e.g. BACPR 2017; NICE 2018; Piepoli
2016), although there is a move toward diDerent sorts of targeting
of psychological interventions, for example, mood states (Reavell
2018), and adherence to lifestyle change (Khanji 2018), and
medicines (Bosworth 2018).
The Cochrane Review, Richards 2017, showed that for people with
CHD, psychological interventions did not reduce mortality (from
any cause), or the risk of cardiac surgery or of having another heart
attack. Psychological interventions were found to reduce the risk of
cardiac deaths and participant-reported symptoms of depression,
anxiety and stress. However, participants had varying levels of
psychopathology, and of the 35 included trials 10 did not report
psychological status of participants at baseline despite testing
the eDectiveness of a psychological intervention. Due to the high
proportion of trials having a mixed population (i.e. participants
with and without a reported psychological disorder at baseline,
and trials not reporting psychological status) the evidence remains
equivocal as to whether psychological interventions should solely
target people with CHD and with established psychological
disorders as opposed to mixed populations (Richards 2017;
Richards 2018). To assist in determining whether those in greatest
need benefit most from psychological interventions, the current
review will focus on adults with a diagnosis of HD, with and without
'reported' depression and anxiety.
In summary, CHD, HF and AF (HD) are growing global health and
economic challenges (Cozzolino 2018; Lesyuk 2018; Shafie 2018).
By including the three most prevalent cardiovascular conditions
this Cochrane systematic review will extend previous reviews that
have focused on specific cardiovascular diagnoses (Carney 2017;
Lichtman 2014; Richards 2017; Whalley 2011). Further, comparison
of trials of psychological interventions for people with HD, with and
without reported depression or anxiety, will assist in determining
the possible eDicacy in these subpopulations.
Description of the intervention
This review will include psychological interventions delivered by
healthcare workers who have been trained in their delivery. In the
case of interventions that are delivered online, we will consider
all psychological interventions targeting depression or anxiety
developed by psychologists or healthcare workers with training in
psychological techniques. By nature, psychological interventions
are varied (i.e. content, composition), ranging from traditional
psychological therapies (e.g. cognitive behavioural therapy) used
to identify and correct dysfunctional emotions, behaviours and
cognitions through a goal-orientated, systematic procedure in
people with cardiac conditions (Kaplan 2009), to third-wave
cognitive behavioural therapies (e.g. mindfulness-based stress
reduction).
In 2009, National Institute of Health and Care Excellence (NICE)
first published guidelines for eDective delivery of psychological
interventions for depression among those with chronic health
conditions. The guidelines stipulated that interventions of this
type be delivered by competent delivery agents or practitioners
and advocated a more structured approach to guide interventions
(NICE 2009). Accordingly, this review will focus on psychological
interventions addressing depression and anxiety in HD delivered
by healthcare workers trained in the delivery of the intervention
and for those delivered online, developed by psychologists or
healthcare workers with training in psychological techniques.
Best practice guidelines advocate that people diagnosed with
HD are oDered cardiac rehabilitation (CR; BACPR 2017; Lichtman
2014; NICE 2018; Piepoli 2016; Ponikowski 2016; WoodruDe
2015). The following definition encompasses the key concepts
of CR: “The coordinated sum of activities required to influence
favourably the underlying cause of cardiovascular disease, as
well as to provide the best possible physical, mental and social
conditions, so that the patients may, by their own eDorts,
preserve or resume optimal functioning in their community and
through improved health behaviour, slow or reverse progression
of disease” (BACPR 2017, p.1). Typical components of CR consist
of assessment and management plans, health behaviour change
and education, lifestyle risk factor management (diet, smoking,
exercise), medication management and psychosocial health (Dalal
2015; Thomas 2019). Psychosocial components in CR programmes
were introduced to enhance HRQoL, increase treatment adherence
and improve cardiovascular prognosis (Pogosova 2015). However,
oLen dependent on resource availability and geographic location,
CR programmes vary in their core components, intensity, duration,
setting and delivery team. For example, less than one quarter
of CR programmes across the UK provide specific psychological
treatments (NACR 2018). Furthermore, a recent cross-sectional
study of CR in 111 countries identified significant regional variation
and relatively low numbers of programmes that included a
psychosocial component (Supervia 2019). Notwithstanding, the
benefits of CR are well established, including increased HRQoL,
and reductions in rehospitalisation, morbidity and mortality rates
(Anderson 2016; Long 2019). This review will include psychological
interventions delivered alone or with CR, as long as CR was part of
usual medical care and oDered routinely to both trial arms.
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Evidence-based guidelines recommend medication (e.g. selective
serotonin reuptake inhibitors or selective serotonin norepinephrine
reuptake inhibitors) as a first-step therapy in the treatment of
major depressive disorder (MDD; Jobst 2016; Qaseem 2016).
Current evidence reports that adjunct use of pharmacotherapy
for an underlying psychological condition may increase
intervention eDectiveness compared with interventions without
pharmacotherapy (Richards 2017; Richards 2018). However,
pharmacotherapy treatment for mental health disorders can
present cardiovascular risk due to side eDects of the drugs or
interactions with other medications (Pina 2018). People most
likely to receive medication are those with the most severe forms
of depressive illness (Gartlehner 2017). Including people across
the spectrum of disease severity is essential to determining who
benefits the most from psychological intervention. This review
will include psychological interventions, with and without adjunct
pharmacotherapy.
How the intervention might work
There is considerable evidence that depression and anxiety
are risk factors for the development of HD (Dhar 2016), with
depression an established independent risk factor of CHD (Van
Der Kooy 2007). Both are strongly associated with poor cardiac
outcomes (Carney 2017; May 2017; Seldenrijk 2015). Those with
established HD are likely to experience depression and anxiety with
prevalence rates frequently reported at around 40% (Colquhoun
2013; Seldenrijk 2015), and some large-scale trials reporting levels
of depression over 60% (Carney 2004; Kotseva 2009). Hence,
the evidence for a bidirectional relationship between negative
emotional states and HD is substantial. While the pathways
are not completely understood, factors impacting on poorer
prognosis of people with HD and with depression or anxiety,
or both, are multifactorial, including lifestyle, behavioural and,
more recently, biological. Lifestyle and behavioural factors include
increased rates of smoking, alcohol intake, physical inactivity,
and obesity (Dhar 2016). MDD is also a predictor of poor disease
treatment, management and medication adherence (Bauer 2012;
Goldstein 2017). For example, patients who are depressed are
far less likely to be motivated to complete or even attend CR
programmes (Chauvet-Gelinier 2017). MDD can cause autonomic
nervous system dysfunction, elevated cortisol levels, and elevated
markers of inflammation with subsequent deleterious downstream
eDects, including hypertension, leL ventricular hypertrophy, and
coronary vasoconstriction (Dhar 2016). The evidence is building
to suggest that both depression and anxiety contribute to
the pathogenesis of HD (O’Neill 2016; Seldenrijk 2015). Of
significance is the growing recognition of the role of psychological
determinants in cardiac illness and recovery (Chauvet-Gelinier
2017), which has implications for psychological interventions
and subsequent adoption and maintenance of healthy lifestyle
behaviours, medication adherence and potential for improved
clinical outcomes in those with HD.
Why it is important to do this review
In their 2017 Cochrane Review, Richards 2017, according to GRADE
methodology, concluded that uncertainty remains regarding
the benefits of psychological interventions among people with
CHD (i.e. reducing cardiac mortality and reducing psychological
symptoms), and large-scale trials are still warranted. The current
review will include HF and AF in addition to CHD, thus increasing
the likelihood of the inclusion of additional large-scale trials
in the existing evidence base. Adding to the uncertainty was
the number of trials with no reported psychopathologies at
baseline (Richards 2017). This review will include people with
HD with reported levels (including scores indicating absence) of
depression or anxiety at baseline, which will add to the knowledge
base on the eDectiveness of optimally targeted psychological
interventions. Further, many national and international CVD
secondary prevention and rehabilitation guidelines acknowledge
the importance of the provision of psychological interventions in
addition to standard rehabilitation (Lichtman 2014; NICE 2009;
Piepoli 2016; WoodruDe 2015), especially in people with depression
or anxiety with comorbid CVD, and will therefore benefit from the
evidence of this review.
O B J E C T I V E S
To assess the eDicacy and costs of psychological interventions
(alone, or with CR or pharmacotherapy, or both) in adults who
have a diagnosis of CHD, HF or AF compared to no intervention, or
treatment as usual, on psychological and clinical outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) with parallel-group,
individual participant or cluster-allocation design comparing the
independent eDects of a psychological intervention versus a usual-
care comparator. We will consider RCTs where follow-up was
six months or more following the start of the intervention or
randomisation. We will include trials reported as full text, those
published as abstract only, and unpublished data.
Types of participants
Adults, 18 years of age and older with HD, with and without
depression or anxiety, managed in either hospital or community
settings. Participants with HD will include people who had a
clinical diagnosis of CHD, HF or AF. Participants with CHD will
include those who have experienced a myocardial infarction (MI),
a revascularisation procedure, such as coronary artery bypass graL
(CABG) or percutaneous coronary intervention (PCI), and people
with angina, or angiographically defined CHD. Participants with HF
will include reduced (< 40%) ejection fraction (HFrEF), mid-range
(40% to 49%) ejection fraction (HFmrEF) and those with preserved
(≥ 50%) ejection fraction HF (HFpEF; Ponikowski 2016; Watson
2018). We will include participants with all types of AF. Participants
may have comorbid conditions (alongside HD).
However, we will exclude trials if the population is mixed, for
example, participants with CHD or diabetes, and the data are not
stratified by condition. Only if more than 50% of participants are
ineligible for this review will we exclude the trial. We will also
exclude trials including participants without a baseline assessment
of depression or anxiety, patient-reported or otherwise. Prior to
excluding any such trials, we will contact the trial authors to request
the data for the subgroup of interest.
Types of interventions
We will consider all psychological interventions targeting
depression or anxiety delivered by psychologists or healthcare
workers with specific training in psychological techniques. For
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interventions delivered online, we will consider all psychological
interventions targeting depression or anxiety developed by
psychologists or healthcare workers with training in psychological
techniques. Included interventions may vary in content and
composition, ranging from cognitive behavioural therapies (e.g.
rational emotive therapy, restructuring), to third-wave cognitive
behavioural therapies (e.g. mindfulness-based stress reduction).
We will classify psychological interventions as per the Cochrane
Common Mental Disorders (CCMD) classification of psychological
interventions (CCMD 2019). We will exclude less specific
approaches, such as therapeutic counselling or educational
interventions from this delineation, along with self-management
techniques used to change cardiac risk factors such as smoking and
low levels of exercise. We will exclude trials that do not specify that
healthcare workers delivering the intervention were specifically
trained, or following a treatment protocol. When uncertainty
exists, prior to excluding any such trials, we will contact the
trial authors to determine whether specific training took place.
We will exclude trials where evaluation of the intervention is
solely directed at improving adherence to other cardiovascular
eDicacious treatments (e.g. medications, exercise) or modifying
lifestyle factors (e.g. smoking, diet). We will only consider trials
where the eDect of the psychological intervention can be evaluated
independently.
We will include trials that compare psychological treatment
with usual care. Usual care may include routine medical care
provided to people with HD, and co-interventions including
referral to or participation in (or both) a comprehensive CR
programme. Although psychological interventions oLen include
co-interventions (e.g. cardiac risk factor education), we will
exclude trials where the co-interventions are not oDered in usual
care. We will include trials of psychological interventions oDered
in conjunction with pharmacotherapy (Richards 2017). These
interventions will be eligible for inclusion as long as the eDect of the
psychological intervention can be evaluated independently from
co-interventions.
Types of outcome measures
Primary outcomes
1. Depression (continuous outcome)
2. Depression (dichotomous outcome)
3. Anxiety (continuous outcome)
4. Anxiety (dichotomous outcome)
We will measure depression and anxiety as change in symptoms
(mean score), unless trials report binary data (cut-oD points)
only. We will analyse continuous and dichotomous outcomes
separately and we will accept psychometrically validated measures
of depression or anxiety, self-reported or other, along with clinical
diagnosis. The primary time point for anxiety and depression will
be at six-month follow-up, and similarly for secondary outcomes.
Validated tools for depression include: Beck’s Depression Inventory
(BDI; Beck 1961); Beck’s Depression Inventory II (BDI II; Beck
1996); Behavioral Activation for Depression Scale (BADS; Kanter
2007); Cardiac Depression Scale (CDS; Hare 1996); Center for
Epidemiological Studies Depression Scale (CES-D; RadloD 1977);
Comprehensive Psychopathological Rating Scale (CPRS; Asberg
1978); Comprehensive Psychopathological Rating Scale Self-
ADective (CPRS S-A; Svanborg 1994); Depression, Anxiety and
Stress Scale (DASS21; Lovibond 1995); Delusions-Symptoms-States
Inventory/states of Anxiety and Depression (DSSI/sAD; Bedford
1976); Hospital Anxiety and Depression Scales (HADS-D; Zigmond
1983); Hamilton Depression Rating Scale (HAM-D; Hamilton 1960);
Maastricht Questionnaire for Vital Exhaustion and Depression
(Williams 2010); Montgomery-Åsberg Depression Rating Scale
(MADRS; Montgomery 1979); Patient Health Questionnaire-9
(PHQ-9; Kroenke 2001); Symptom Checklist 90-R (SCL-90-R;
Derogatis 1992); Zung Self-Rating Depression Scale (ZDS; Zung
1965).
Validated tools for anxiety include: Beck's Anxiety Inventory
(BAI; Beck 1988); Cardiac Anxiety Questionnaire (CAQ; Eifert
2000); Delusions Symptoms States Inventory/states of Anxiety
and Depression (DSSI/sAD; Bedford 1976); Generalised Anxiety
Disorder Assessment (GAD-7; Spitzer 2006); Hospital Anxiety
and Depression Scales (HADS-A; Zigmond 1983); Overall Anxiety
Severity and Impairment Scale 9OASIS (Campbell-Sills 2009); State-
Trait Anxiety Inventory (STAI; Spielberger 1983); Symptom Checklist







5. All-cause hospitalisations (participants with at least one event)
6. Cardiovascular hospitalisations (participants with at least one
event)
7. Cardiovascular morbidity: non-fatal MI (participants with at
least one event)
8. Cardiovascular morbidity: revascularisation (CABG, PCI;




11.Costs and cost-eDectiveness: costs per quality-adjusted life
years (QALYs)
12.Adverse events
Validated tools for HRQoL include: Cantril Self-Anchoring Striving
Scale (Ladder of Life; Cantril 1965); Chronic Heart Failure
Assessment Tool (CHAT; Dunderdale 2008); Chronic Heart Failure
Questionnaire (CHFQ; Guyatt 1989); Dartmouth COOP scales
(Nelson 1987); EuroQol-5D (EQ-5D; Rabin 2001); HeartQoL
(Oldridge 2014); Kansas City Cardiomyopathy Questionnaire
(KCCQ; Green 2000); Karnofsky Performance Status Scale (Schag
1984); LeL Ventricular Disease Questionnaire (LVDQ; O’Leary
2000); MacNew Questionnaire (Valenti 1996); Minnesota Living
with Heart Failure Questionnaire (LHFQ; Rector 1987); Myocardial
Infarction Dimensional Assessment Scale (MIDAS; Thompson 1998);
Psychological General Well-Being Index (Dupuy 1984); Quality of
Life Questionnaire in Severe Heart Failure (QLQ-SHF; Wiklund
1987); Seattle Angina Questionnaire (Spertus 1995); Short Form
Health Survey 36 (SF-36; Ware 1994); Short Form Health Survey
(SF-12; Ware 1995).
Validated tools for self-eDicacy include: Generalized Self-EDicacy
Scale (GES; Schwarzer 1995); General Self-EDicacy Scale (GES-6;
Psychological interventions for depression and anxiety in patients with coronary heart disease, heart failure or atrial fibrillation
(Protocol)









Cochrane Database of Systematic Reviews
Romppel 2013); New General Self-EDicacy Scale (NGSE; Chen 2001);
Self-eDicacy Survey (Panc 2013).
We will assess intervention acceptability using 1) retention rates
and 2) reporting a narrative summary of qualitative data on utility,
adherence, barriers and satisfaction (Sekhon 2017; Saracutu 2018).
We will report adverse events in a narrative summary, including
a notable absence of evidence addressing whether there are
adverse outcomes arising from participation in a psychological
intervention.
Reporting one or more of the above-listed primary and secondary
outcomes in the trial is not an inclusion criterion for the review.
Where a published report does not appear to report one of these
outcomes, we will access the trial protocol and contact the trial
authors to ascertain whether the outcomes were measured but not
reported.
Where reported we will assess primary and secondary outcomes
at time points longer than 12 months and capture the longest
available follow-up. As part of the narrative, we will include in the
review relevant trials, which measured these outcomes but did not
report the data at all, or not in a usable format.
Search methods for identification of studies
Electronic searches
We will identify trials through systematic searches of the following
bibliographic databases:
1. Cochrane Central Register of Controlled Trials (CENTRAL) in the
Cochrane Library
2. MEDLINE (Ovid, from 2009 onwards)
3. Embase (Ovid, from 2009 onwards)
4. PsycINFO (Ovid, from 2009 onwards)
5. CINAHL (EBSCO, from 2009 onwards)
We will adapt the preliminary search strategy (see (Appendix 1) for
MEDLINE (Ovid) for use in the other databases and we will apply the
Cochrane Sensitivity-precision maximising RCT filter to MEDLINE
(Ovid) and adaptations of it to the other databases, except CENTRAL
(Lefebvre 2019).
We will also conduct a search of ClinicalTrials.gov
(www.ClinicalTrials.gov), and the World Health Organization
International Clinical Trials Registry Platform (WHO ICTRP) Search
Portal (apps.who.int/trialsearch/), for ongoing or unpublished
trials.
We will search all databases from 2009 (in accordance with NICE
2009 guidelines) to the present, and we will impose no restriction
on language of publication or publication status. In 2009 there
were many scientific advances in understanding the relationship
between depression and CVD, with lasting implications for the
treatment of depression in people with CVD (Davidson 2010). These
advances included publication of results from three RCTs reporting
the eDicacy of depression interventions in people with CVD (Carney
2009; Freedland 2009; Rollman 2009). In late 2008 the American
Heart Association released a science advisory, Depression and
coronary heart disease: recommendations for screening, screening
referral and treatment (Lichtman 2014). In 2009 NICE first published
guidelines for eDective delivery of psychological interventions
for depression among those with chronic health conditions,
with particular attention paid to heart disease (NICE 2009).
The guidelines advocated a more structured approach to guide
interventions and stipulated that interventions of this type be
delivered by competent delivery agents or practitioners (NICE
2009).
We will not perform a separate search for adverse eDects
resulting from psychological interventions used for the treatment
of depression or anxiety. We will consider adverse eDects described
in included trials only.
Searching other resources
We will search by hand the reference lists of all included trials and
previous systematic reviews for additional references to trials. We
will contact the main authors of included trials and experts within
the area to ask for any missed, unreported or ongoing trials. We will
also search for any retraction statements and errata for included
trials.
Data collection and analysis
Selection of studies
Two review authors (CFS and KMcG) will independently screen titles
and abstracts for inclusion of all the potential trials we identify
as a result of the search and code them as 'retrieve' (eligible or
potentially eligible/unclear) or 'do not retrieve'. If there are any
disagreements, a third author will be asked to arbitrate (JDL). We
will retrieve the full-text trial reports/publication and two review
authors (CFS and KMcG) will independently screen the full-text and
identify trials for inclusion, and identify and record reasons for
exclusion of the ineligible trials. We will resolve any disagreement
through discussion or, if required, we will consult a third person
(JDL). We will identify and exclude duplicates and collate multiple
reports of the same trial so that each trial rather than each report
is the unit of interest in the review. We will record the selection
process in suDicient detail to complete a PRISMA flow diagram and
'Characteristics of excluded studies' table (Liberati 2009).
Data extraction and management
We will use a data collection form for trial characteristics and
outcome data, which has been piloted on at least one trial in the
review (Richards 2017). One review author (CFS and KMcG) will
extract trial characteristics from included trials. We will extract the
following study characteristics.
1. Methods: trial design, total duration of trial, number of trial
centres and location, trial setting, and date of trial
2. Participants: number randomised, number lost to follow-up/
withdrawn, number analysed, mean age, age range, gender,
severity of condition, diagnostic criteria, inclusion criteria, and
exclusion criteria
3. Interventions: intervention (including the goals of treatment
and components used to achieve those goals), comparison, and
co-interventions. We will describe psychological interventions
as per CCMD classifications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported
5. Notes: funding for trial, and notable conflicts of interest of trial
authors
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Two review authors (CFS and KMcG) will independently extract
outcome data from included trials. We will resolve disagreements
by consensus or by involving a third person (JDL). However, we
will extract only ‘new’ variables for papers that were included in
Richards 2017. One review author (CFS) will transfer data into the
Review Manager 5 (Review Manager 2014) file. We will double-
check that data are entered correctly by comparing the data
presented in the systematic review with the data extraction form.
A second review author (KMcG) will spot-check trial characteristics
for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (CFS and KMcG) will independently assess
risk of bias for each trial according to the Cochrane 'Risk of bias'
tool, RoB2 (Higgins 2019a). We will resolve any disagreements by
discussion or by involving another review author (JDL). We will
assess the risk of bias of specific results of a trial according to the
following domains:
1. Bias arising from the randomisation process
2. Bias due to deviations from intended interventions
3. Bias due to missing outcome data
4. Bias in measurement of the outcome
5. Bias in selection of the reported result
6. Bias arising from identification or recruitment of individual
participants within clusters
We included domain 6 as per the revised Cochrane 'Risk of bias
tool' for randomized trials (RoB 2) (Sterne 2019). If cluster-RCTs are
included we will consider whether the reported data analysis had
appropriately taken account of the aggregate nature of the data.
We will pay particular attention to randomisation processes (e.g.
allocation sequence, timing, baseline imbalances) and blinding
(e.g. recruitment bias, identification bias) (Eldridge 2016).
We will assess the risk of bias for the outcomes of the included
trials that will be included in our 'Summary of findings' table
according to the eDect of assignment to the interventions at
baseline, regardless of whether the interventions are received as
intended (the ‘intention-to-treat eDect’).
We will use the signalling questions in RoB2 and rate each domain
as 'low risk of bias', 'some concerns' or 'high risk of bias'. We will
summarise the 'Risk of bias' judgements across diDerent trials for
each of the domains listed for each outcome. The overall risk of
bias for the result will be the least favourable assessment across
the domains of bias. Where information on risk of bias relates to
unpublished data or correspondence with a trial author, we will
note this in the 'Risk of bias' table. Thus, "A judgement of ‘High’
risk of bias for any individual domain will lead to the result being
at ‘High’ risk of bias overall, and a judgement of ‘Some concerns’
for any individual domain will lead to the result being at ‘Some
concerns’, or ‘High’ risk, overall" (Sterne 2019).
When considering treatment eDects, we will take into account the
risk of bias for the trials that contribute to that outcome.
Assessment of bias in conducting the systematic review
We will conduct the review according to this published protocol and
report any deviations from it in the 'DiDerences between protocol
and review' section of the systematic review.
Measures of treatment e:ect
Dichotomous outcomes for each comparison will be expressed as
risk ratios with 95% confidence intervals. Continuous data will
be expressed as mean diDerence with 95% confidence intervals,
or where an outcome is measured and reported in more than
one way, as standardised mean diDerence with 95% confidence
intervals. We will express continuous data as the mean change (and
standard deviation (SD)) in outcomes between baseline and follow-
up for both psychological intervention and control groups; when
not available, we will use the absolute mean (and SD) outcome at
follow-up for both groups. We will report event trial sample sizes
based on the number randomised to treatment conditions.
We will consider treatment eDects for depression, anxiety and
HRQoL in terms of clinically meaningful diDerences, for example,
we will consider a 1.5 diDerence on the HADS as clinically
meaningful (Puhan 2008), and a 5-point diDerence on the MLWHF
questionnaire as clinically meaningful (Rector 1992).
We will narratively describe skewed data reported as medians and
interquartile ranges.
Unit of analysis issues
For trials with more than one relevant intervention arm included
in the same analysis, we will divide the number randomised in the
control group by the number of intervention arms to obtain the
denominator for data analysis. In accordance with Section 9.3.4
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2019b), if we include data with repeated observations on
participants, we will define several outcomes based on diDerent
periods of follow-up and conduct separate analyses. Analysis will
include all trials with measurement at the end of intervention
(post-test). If we include cluster-RCTs, we will consider whether
the reported data analysis has appropriately taken account of the
aggregate nature of the data.
Dealing with missing data
We will contact investigators or trial sponsors in order to verify
key trial characteristics and obtain missing numerical outcome
data where possible (e.g. when a trial is identified as abstract
only). Where possible, we will use the Review Manager 5 calculator
to calculate missing SDs using other data from the trial, such
as confidence intervals (Review Manager 2014). Where this is not
possible, and the missing data are thought to introduce serious
bias, we will explore the impact of including such trials in the overall
assessment of results by a sensitivity analysis.
Assessment of heterogeneity
We will inspect forest plots visually to consider the direction and
magnitude of eDects and the degree of overlap between confidence
intervals. We will use the I2 statistic (Higgins 2003), to measure
heterogeneity among the trials in each analysis, but acknowledge
that there is substantial uncertainty in the value of I2 statistic when
there is only a small number of trials. We will also consider the
P value from the Chi2 test (Deeks 2019). If we identify substantial
heterogeneity we will report it and explore possible causes by
prespecified subgroup analysis.
We will use a threshold of I2 statistic value greater than 50%
(considered to represent substantial heterogeneity; section 10.10.2
of the Cochrane Handbook for Systematic Reviews of Interventions)
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for both dichotomous and continuous outcomes to determine the
statistical model to be used for meta-analysis (Deeks 2019).
Assessment of reporting biases
If we are able to pool more than 10 trials, we will create and examine
a funnel plot and the Egger test to explore possible small trial biases
for the primary outcomes (Egger 1997).
Data synthesis
We will undertake meta-analyses only where this is meaningful,
that is, if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense. As
heterogeneity is expected for psychological interventions, we will
pool data from each trial using a random-eDects model. This
will provide a more conservative statistical comparison of the
diDerence between intervention and control because a confidence
interval around the eDect estimate is wider than a confidence
interval around a fixed-eDect estimate. Due to the tendency of
smaller trials, which are more susceptible to publication bias, to be
over-weighted with a random-eDects model we will also conduct a
sensitivity analysis using the fixed-eDect pooled estimate and 95%
confidence interval (Heran 2008a; Heran 2008b). We will complete
data synthesis and analyses using Review Manager 5 soLware
(Review Manager 2014). For primary and secondary outcomes,
where there were insuDicient data, or where it is inappropriate to
combine trials statistically, we will present a narrative review using
the vote-counting method (Hedges 1980).
'Summary of findings' table
We will create a 'Summary of findings' table using the following
outcomes: depression, anxiety, HRQoL, all-cause mortality,
cardiovascular mortality, cardiovascular hospitalisations and cost-
eDectiveness. We will use the five GRADE considerations (trial
limitations, consistency of eDect, imprecision, indirectness and
publication bias) to assess the certainty of a body of evidence
as it relates to the trials that contribute data to the meta-
analyses for the prespecified outcomes. We will use methods
and recommendations described in Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Schünemann
2019), using GRADEpro soLware (GRADEpro GDT). We will justify all
decisions to downgrade the certainty of trials using footnotes and
we will make comments to aid reader's understanding of the review
where necessary.
Two review authors (CFS and KMcG), working independently, will
make Judgements about evidence certainty with disagreements
resolved by discussion or by involving a third review author (JDL).
We will justify judgements, document them and incorporate them
into reporting of results for each outcome.
We plan to extract trial data, format our comparisons in data tables
and prepare a 'Summary of findings' table before writing the results
and conclusions of our review. A template 'Summary of findings
table' is included as Table 1.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Trials of psychological interventions with and without co-
intervention of CR
2. Trials of psychological interventions with and without co-
intervention of pharmacotherapy
3. Trials of psychological interventions with and without co-
interventions of CR and pharmacotherapy
4. Trials of psychological interventions targeting HD population
(CHD or AF or HF)
5. Trials of psychological interventions targeting population with
depression or anxiety, or those not specified
6. Trials with analysis of mode of psychological intervention
(individual or group or combined individual and group)
7. Trials of psychological interventions with and without family
involved in intervention
8. Trials of psychological interventions specifically targeting
depression or anxiety or not
9. Trials that employ diDerent treatment components, that
is, relaxation, stress management techniques, cognitive
techniques, emotional support or client-led discussion, or
combinations
We will explore potential heterogeneity in psychological
interventions via three approaches:
1. detailed tabulation of population, intervention and
comparators for each trial;
2. within-trial subgroup analyses (supported by subgroup x
intervention/control interaction terms); and
3. between-trial analyses via meta-regression.
We will use meta-regression to examine the association between
eDects of all outcomes this applies to that are reported up to
six months. We will perform meta-regression analyses using the
’metareg’ command in STATA (StataCorp 2019).
Sensitivity analysis
We plan to carry out the following sensitivity analyses, to test
whether key methodological factors or decisions have aDected the
main result.
1. Only including trials with a low risk of bias according to the RoB2
tool
2. When it is not possible to calculate missing SDs and the missing
data are thought to introduce bias
3. The assumption of heterogeneity using a fixed-eDect pooled
estimate and 95% confidence interval
Reaching conclusions
We will base our conclusions only on findings from the quantitative
or narrative synthesis of included trials for this review. We will
avoid making recommendations for practice and our implications
for research will suggest priorities for future research and outline
what the remaining uncertainties are in the area.
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Intervention versus control for the treatment of depression or anxiety, or both
Patient or population: people with heart disease

























Depression            
Anxiety            
HRQoL            
All-cause mortality            
Cardiovascular mortality            
Cardiovascular hospitalisations            
Cost effectiveness            
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: confidence interval; HRQoL: health-related quality of life; RCT: randomised controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the
effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the
estimate of effect.
Table 1.   Intervention versus control for the treatment of depression or anxiety, or both 
 
 
A P P E N D I C E S
Appendix 1. Preliminary MEDLINE (Ovid) search strategy
1 exp Heart Diseases/
2 (heart adj4 disease*).tw.
3 exp Coronary Disease/
4 (coronary adj2 disease*).tw.
5 CHD.tw.
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6 exp Heart Failure/
7 (heart adj6 fail*).tw.
8 exp Atrial Fibrillation/
9 Atrial fibrillation.tw.
10 exp Myocardial Ischemia/
11 (myocard* adj4 (ischaemi* or ischemi*)).tw.
12 ((ischaemi* or ischemi*) adj4 heart).tw.
13 exp Myocardial Infarction/
14 (myocard* adj4 infarct*).tw.
15 (heart adj4 (infarct* or attack*)).tw.
16 exp Angina Pectoris/
17 angina.tw.
18 stenocardia*.tw.
19 exp Percutaneous Coronary Intervention/
20 (percutaneous coronary adj2 (interven* or revascular*)).tw.
21 (pci or ptca).tw.
22 exp Coronary Artery Bypass/
23 (coronary adj4 bypass*).tw.
24 CABG.tw.
25 aortocoronary bypass*.tw.
26 Heart Bypass, LeL/ or Heart Bypass, Right/











38 acute coronary syndrom*.tw.
39 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38
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40 exp Psychotherapy/
41 psychotherap*.tw.
42 ((psycholog* or psychosocial) adj intervent*).tw.




47 (counselling or counseling).tw.
48 Stress, Psychological/







56 Cognitive Behavioral Therapy/
57 (cognitive adj4 (therap* or technique*)).tw.
58 CBT.tw.
59 ((behavior* or behaviour*) adj4 (modify or modificat* or therap* or change)).tw.





65 (goal* adj3 setting).tw.
66 (psycho-educat* or psychoeducat*).tw.
67 (motivat* adj3 interv*).tw.
68 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63
or 64 or 65 or 66 or 67
69 39 and 68
70 randomized controlled trial.pt.
71 controlled clinical trial.pt.
72 randomized.ab.
73 placebo.ab.
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74 clinical trials as topic.sh.
75 randomly.ab.
76 trial.ti.
77 70 or 71 or 72 or 73 or 74 or 75 or 76
78 exp animals/ not humans.sh.
79 77 not 78
80 69 and 79
81 limit 80 to yr="2009-current"
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